Cocrystal Pharma vs NanoViricides
COCP and NNVC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How COCP and NNVC compare
NanoViricides is the larger company, worth 1.7 times as much as Cocrystal Pharma ($31.4M against $18.9M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | COCP | NNVC |
|---|---|---|
| Size and price | ||
| Market cap | $18.9M | $31.4M |
| Share price | $0.980 | $1.23 |
| Change, 1 year | −10.9% | −18.0% |
| Change, 5 years | −90.0% | −73.2% |
| Beta (5Y) | 1.13 | 0.77 |
| Employees | 10 | 7 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 18.1× | 3.6× (better) |
| FCF yield | – | −24.8% |
| Profitability | ||
| Return on equity | −312% | −101% (better) |
| Return on invested capital | – | −111% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.24 | 2.66 (better) |
| Altman Z-score | −108.58 | −9.11 (better) |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −6.1% |
| Shareholder yield | 0.00% (better) | −6.1% |
| Ownership | ||
| Held by institutions | 5.8% | 9.3% |
| Held by insiders | 60.3% | 0.00% |
| Insider net buying, 12 months | $278K | – |
| Short interest, % of float | 2.4% | 3.2% |
Go deeper
- COCP stock overview
- COCP income statement
- COCP valuation and score
- NNVC stock overview
- NNVC income statement
- NNVC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.